The management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 14, Issue 4, 2010, Pages 256-273

  Chen, Tzong Huei ^a   Matyal, Robina ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

antiplatelet therapy; coronary stents; noncardiac surgery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; THROMBOXANE A2; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; COMORBIDITY; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; DRUG CLEARANCE; DRUG EFFECT; DRUG ELUTING STENT; HEART INFARCTION; HEART SURGERY; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIOPERATIVE PERIOD; RESTENOSIS; RISK FACTOR; STENT THROMBOSIS; THROMBOCYTE TRANSFUSION;

CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STENTS; SURGICAL PROCEDURES, ELECTIVE; SURGICAL PROCEDURES, OPERATIVE; THROMBOSIS; TIME FACTORS;

EID: 78650827820     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253210386244     Document Type: Article

References (119)

1. Holmes DR, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984 ; 53: 77C - 81C.
2. Ueda Y., Nanto S., Komamura K., Kodama K. Neointimal coverage of stents in human coronary arteries observed by angioscopy. J Am Coll Cardiol. 1994 ; 23: 341-346.
3. Bornemann H., Pruller F., Metzler H. The patient with coronary stents and antiplatelet agents: what to do and how to deal ? Eur J Anaesthesiol. 2010 ; 27: 406-410.
4. Newsome LT, Kutcher MA, Royster RL Coronary artery stents: part I. Evolution of percutaneous coronary intervention. Anesth Analg. 2008 ; 107: 552-569.
5. Smith EJ, Rothman MT Antiproliferative coatings for the treatment of coronary heart disease: what are the targets and which are the tools ? J Interv Cardiol. 2003 ; 16: 475-483.
6. Dehmer GJ, Smith KJ Drug-eluting coronary artery stents. Am Fam Physician. 2009 ; 80: 1245-1251.
7. Rade JJ, Hogue CW Jr. Noncardiac surgery for patients with coronary artery stents: timing is everything. Anesthesiology. 2008 ; 109: 573-575.
8. Alfonso F. The "vulnerable" stent: why so dreadful ? J Am Coll Cardiol. 2008 ; 51: 2403-2406.
9. Joner M., Finn AV, Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 ; 48: 193-202.
10. Awata M., Kotani J., Uematsu M., et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007 ; 116: 910-916.
11. Chen BX, Ma FY, Luo W., et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart. 2008 ; 94: 566-570.
12. Steffel J., Latini RA, Akhmedov A., et al. Rapamycin, but Not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005 ; 112: 2002-2011.
13. Stahli BE, Camici GG, Steffel J., et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun Terminal NH2 kinase activation. Circ Res. 2006 ; 99: 149-155.
14. Babinska A., Markell MS, Salifu MO, et al. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant. 1998 ; 13: 3153-3159.
15. Ong ATL, Hoye A., Aoki J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005 ; 45: 947-953.
16. Auer J., Leitner A., Berent R., et al. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation. Atherosclerosis. 2010 ; 210: 503-509.
17. Chou S., Eshaghian S., Lamer A., et al. Bridging therapy in the perioperative management of patients with drug-eluting stents. Rev Cardiovasc Med. 2009 ; 10: 209-218.
18. Holmes DR, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007 ; 50: 109-118.
19. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006 ; 98: 352-356.
20. Luscher TF, Steffel J., Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007 ; 115: 1051-1058.
21. Jaffe R., Strauss BH Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol. 2007 ; 50: 119-127.
22. Jensen LO, Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007 ; 50: 463-470.
23. Pfisterer M., Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006 ; 48: 2584-2591.
24. Assali A., Vaknin-Assa H., Lev E., et al. The risk of cardiac complications following noncardiac surgery in patients with drug eluting stents implanted at least six months before surgery. Catheter Cardiovasc Interv. 2009 ; 74: 837-843.
25. Abbott JD, Voss MR, Nakamura M., et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the national heart, lung, and blood institute dynamic registry. J Am Coll Cardiol. 2007 ; 50: 2029-2036.
26. Rabbitts JA, Nuttall GA, Brown MJ, et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology. 2008 ; 109: 596-604.
27. Nuttall GA, Brown MJ, Stombaugh JW, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology. 2008 ; 109: 588-595.
28. Chechi T., Vecchio S., Vittori G., et al. ST-Segment elevation myocardial infarction due to early and late stent thrombosis: a new group of high-risk patients. J Am Coll Cardiol. 2008 ; 51: 2396-2402.
29. Meier P., Zbinden R., Togni M., et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol. 2007 ; 49: 15-20.
30. Patrono C., Baigent C., Hirsh J., Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008 ; 133: 199S - 233S. (Pubitemid 351894914)
31. Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur Heart J 2009 ; 30: 1964-1977.
32. Gross PL, Weitz JI New antithrombotic drugs. Clin Pharmacol Ther. 2009 ; 86: 139-146.
33. May AE, Geisler T., Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting: a double-edged sword between thrombosis and bleeding. Thromb Haemost. 2008 ; 99: 487-493.
34. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006 ; 47: 216-235.
35. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008 ; 51: 172-209.
36. Kushner FG, Hand M., Smith SC Jr, et al. 2009 Focused updates: ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009 ; 54: 2205-2241.
37. DeLuca G., Carbone G., Maione A., Gregorio G. In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report. Int J Cardiol. 2007 ; 116: 399-400.
38. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious ? Circulation. 2004 ; 109: 701-705.
39. Choi SH, Prasad A., Tsimikas S. The evolution of thienopyridine therapy: clopidogrel duration, diabetes, and drug-eluting stents. J Am Coll Cardiol. 2008 ; 51: 2228-2229.
40. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010 ; 362: 1374-1382.
41. Vicenzi MN, Meislitzer T., Heitzinger B., et al. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth. 2006 ; 96: 686-693.
42. Kaluza GL, Joseph J., Lee JR, Raizner ME, Raizner AE Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000 ; 35: 1288-1294.
43. Wilson SH, Fasseas P., Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol. 2003 ; 42: 234-240.
44. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate ? Catheter Cardiovasc Interv. 2004 ; 63: 141-145.
45. Reddy PR, Vaitkus PT Risks of noncardiac surgery after coronary stenting. Am J Cardiol. 2005 ; 95: 755-757.
46. Brichon P-Y., Boitet P., Dujon A., et al. Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting. Eur J Cardiothorac Surg. 2006 ; 30: 793-796.
47. Bakhru M., Saber W., Brotman D., et al. Is discontinuation of antiplatelet therapy after 6 months safe in patients with drug-eluting stents undergoing noncardiac surgery? Cleve Clin J Med. 2006 ; 73 (e-suppl1). S23.
48. Compton PA, Zankar AA, Adesanya AO, Banerjee S., Brilakis ES Risk of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol. 2006 ; 98: 1212-1213.
49. Brotman DJ, Bakhru M., Saber W., et al. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. J Hosp Med. 2007 ; 2: 378-384.
50. Schouten O., Van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007 ; 49: 122-125.
51. Godet G., Manach YL, Lesache F., Perbet S., Coriat P. Drug-eluting stent thrombosis in patients undergoing noncardiac surgery: is it always a problem ? Br J Anaesth. 2008 ; 100: 472-477. (Pubitemid 351773621)
52. Vitin AA, Dembo G., Vater Y., et al. Anesthetic implications of the new anticoagulant and antiplatelet drugs. J Clin Anesth. 2008 ; 20: 228-237.
53. Belisle S., Hardy JF Hemorrhage and the use of blood products after cardiac operations: myths and realities. Ann Thorac Surg. 1996 ; 62: 1908-1917.
54. Palmer JD, Sparrow OC, Iannotti F. Postoperative hematoma: a 5-year survey identification of avoidable risk factors. Neurosurgery. 1994 ; 35: 1061-1064.
55. Burger W., Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention- cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005 ; 257: 399-414.
56. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. Anesth Analg. 2001 ; 93: 573-580.
57. Lindblad B., Persson NH, Takolander R., Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled, randomized study. Stroke. 1993 ; 24: 1125-1128.
58. Chen LQ, Bracey AW, Radovancevic R., et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004 ; 128: 425-431.
59. Chu MWA, Wilson SR, Novick RJ, Stitt LW, Quantz MA Does clopidogrel increase blood loss following coronary artery bypass surgery ? Ann Thorac Surg. 2004 ; 78: 1536-1541.
60. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol. 2007 ; 50: e159 - e242.
61. Ernst A., Eberhardt R., Wahidi M., Becker HD, Herth FJF Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest. 2006 ; 129: 734-737.
62. Wiegand UKH, LeJeune D., Boguschewski F. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery. Chest. 2004 ; 126: 1177-1186.
63. Payne DA, Hayes PD, Jones CI, et al. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg. 2002 ; 35: 1204-1209.
64. Chassot PG, Delabays A., Spahn DR Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth. 2007 ; 99: 316-328.
65. Eikelboom JW Bleeding and management of bleeding. Eur Heart J Suppl. 2006 ; 8 (supplG). G38 - G45.
66. Moore M., Power M. Perioperative hemorrhage and combined clopidogrel and aspirin therapy. Anesthesiology. 2004 ; 101: 792-794.
67. Cuthill JA, Young S., Greer IA, Oldroyd K. Anaesthetic considerations in a parturient with critical coronary artery disease and a drug-eluting stent presenting for caesarean section. Int J Obstet Anesth. 2005 ; 14: 167-171.
68. Davies BR Combined aspirin and clopidogrel in cataract surgical patients: a new risk factor for ocular hemorrhage ? Br J Ophthalmol. 2004 ; 88: 1226-1227.
69. The Cardiac Society of Australia and New Zealand. Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery. Heart Lung Circ. 2010 ; 19: 2-10.
70. Chapman TWL, Bowley DMG, Lambert AW, et al. Haemorrhage associated with combined clopidogrel and aspirin therapy. Eur J Vasc Endovasc Surg. 2001 ; 22: 478-479.
71. Di Minno MND, Prisco D., Ruocco AL, et al. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med. 2009 ; 4: 279-288.
72. Ranucci M., Nano G., Pazzaglia A., et al. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth. 2007 ; 21: 851-854.
73. Lauritzen B., Tranholm M., Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost. 2009 ; 7: 651-657.
74. van der Linden J., Lindvall G., Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation. 2005 ; 112: I-276 - I-280.
75. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 ; 293: 2126-2130.
76. Spertus JA, Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER Registry. Circulation. 2006 ; 113: 2803-2809.
77. McFadden EP, Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004 ; 364: 1519-1521.
78. de Souza DG, Baum VC, Ballert NM Late thrombosis of a drug-eluting stent presenting in the perioperative period. Anesthesiology. 2007 ; 106: 1057-1059.
79. Jaffer AK Perioperative management of warfarin and antiplatelet therapy. Clev Clin J Med. 2 009; 76: S37 - S44.
80. Hattori T., Khan MMH, Colman RW, Edmunds LH Plasma tissue factor plus activated peripheral mononuclear cells activate factors vii and x in cardiac surgical wounds. J Am Coll Cardiol. 2005 ; 46: 707-713.
81. de la Torre-Hernandez JM, Alfonso F., Hernandez F., et al. Drug-eluting stent thrombosis: results from the multi-center Spanish Registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008 ; 51: 986-990.
82. Douglas PS, Brennan JM, Anstrom KJ, et al. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol. 2009 ; 53: 1629-1641.
83. Cola C., Brugaletta S., Yuste VM, et al. Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. Vasc Health Risk Manag. 2009 ; 5: 101-119.
84. Best PJM, Lennon R., Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002 ; 39: 1113-1119.
85. El-Menyar AA, Al Suwaidi J., Holmes DR Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency. Mayo Clin Proc. 2010 ; 85: 165-171.
86. Nikolsky E., Kosinski E., Mishkel GJ, et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV Trial). Am J Cardiol. 2005 ; 95: 709-715.
87. Tin-Hay EL, Poh KK, Lim YT, et al. Clinical predictors of stent thrombosis in the "real world" drug-eluting stent era [published online ahead of print June 10, 2009 ]. Int J Cardiol. doi:10.1016/j.ijcard.2009. 1005.1038.
88. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005 ; 45: 954-959.
89. Kuchulakanti PK, Chu WW, Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006 ; 113: 1108-1113.
90. Alfonso F., Suarez A., Perez-Vizcayno MJ, et al. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 ; 50: 2095-2097.
91. Waksman R., Ajani AE, Pinnow E., et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing γ-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 Versus WRIST PLUS. Circulation. 2002 ; 106: 776-778.
92. Rabinovitz A., Bier DM, Wagman GM, et al. Association between off-label use of drug-eluting stents and subsequent stent thrombosis: a case-control analysis. J Invasive Cardiol. 2010 ; 22: 15-19.
93. Beohar N., Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007 ; 297: 1992-2000.
94. Win HK, Caldera AE, Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007 ; 297: 2001-2009.
95. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. Chest. 2008 ; 133: 299S - 339S.
96. Poldermans D., Bax JJ, Boersma E., et al. Task force for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery, European Society of Cardiology; European Society of Anaesthesiology: guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009 ; 30: 2769-2812.
97. Mauermann WJ, Rehfeldt KH, Bell MR, Lowson SM Percutaneous coronary interventions and antiplatelet therapy in the perioperative period. J Cardiothorac Vasc Anesth. 2007 ; 21: 436-442.
98. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007 ; 49: 734-739.
99. Albaladejo P., Marret E., Pririou V., Samama CM Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaesth. 2006 ; 97: 580-585.
100. Howard-Alpe GM, de Bono J., Hudsmith L., et al. Coronary artery stents and non-cardiac surgery. Br J Anaesth. 2007 ; 98: 560-574.
101. Mollmann H., Nef HM, Hamm CW, Elsasser A. How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clin Res Cardiol. 2009 ; 98: 8-15.
102. Eisenberg MJ, Richard PR, Libersan D., Filion KB Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009 ; 119: 1634-1642.
103. Harder S., Klinkhardt U., Alvarez JM Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2004 ; 43: 963-981.
104. Broad L., Lee T., Conroy M., et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth. 2007 ; 98: 19-22.
105. Vasudeva P., Goel A., Sengottayan VK, Sankhwar S., Dalela D. Antiplatelet drugs and the perioperative period: what every urologist needs to know. Indian J Urol. 2009 ; 25: 296-301.
106. Lecompte T., Hardy JF Antiplatelet agents and perioperative bleeding. Can J Anaesth. 2006 ; 53: S103 - S112.
107. Newsome LT, Weller RS, Gerancher JC, Kutcher MA, Royster RL Coronary artery stents: II. Perioperative considerations and management. Anesth Analg. 2008 ; 107: 570-590.
108. Brilakis ES, Banerjee S., Berger PB Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007 ; 49: 2145-2150.
109. Charbucinska KN, Godet G., Itani O., et al. Anticoagulation management for patients with drug-eluting stents undergoing vascular surgery. Anesth Analg. 2006 ; 103: 261-263.
110. Vicenzi MN, Ribitsch D., Luha O., Klein W., Metzler H. Coronary artery stenting before noncardiac surgery: more threat than safety ? Anesthesiology. 2001 ; 94: 367-368.
111. Gurbel PA, DiChiara J., Tantry US Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am J Cardiol. 2007 ; 100 (suppl): 18M - 25M.
112. Jaffe R., Halon DA, Carmeli J., Lewis BS Prolonged intravenous iptifibatide infusion for prevention of coronary stent thrombosis. Int J Cardiol. 2007 ; 114: 409-411.
113. Bigalke B., Seizer P., Geisler T., et al. Perioperative antiplatelet therapy in patients at risk for coronary stent thrombosis undergoing noncardiac surgery. Clin Res Cardiol. 2009 ; 98: 335-339.
114. Newsome LT, Kutcher MA, Gandhi SK, Prielipp RC, Royster RL A protocol for the perioperative management of patients with intracoronary drug-eluting stents. ASPF Newsl. 2006 ; 4: 81-82.
115. Lemon SJ, Flynn JD, Dunn SP Perioperative management of antiplatelet therapy in patients with cardiovascular disease. Orthopedics. 2008 ; 31: 1210.
116. Windecker S., Simon R., Lins M., et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation. 2005 ; 111: 2617-2622.
117. Camici GG, Steffel J., Akhmedov A., et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation. 2006 ; 114: 1512-1521.
118. Aoki J., Serruys PW, van Beusekom H., et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol. 2005 ; 45: 1574-1579.
119. Blindt R., Vogt F., Astafieva I., et al. A novel drug-eluting stent coated with an integrin-binding cyclic arg-gly-asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol. 2006 ; 47: 1786-1795.